ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

BCL6 Degrader TLN-121

Its studies are mostly in Lymphoma, Non-Hodgkin, led by Treeline Biosciences.

Furthest: phase 1, since Jun 26, 20251 company-led study, 1 open or runningNext primary completion: Sep 2030 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Treeline Biosciences11 open or runningphase 1since Jun 26, 2025Jun 26, 2025Sep 2030phase 1 · NCT07082803

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 26, 2025First study: phase 1 study in LymphomaFirst studyNCT07082803 · 180 planned · United States, Australia, Canada

Ahead

  1. Sep 2030Primary completion: phase 1 study in LymphomaNCT07082803

TargetBeta

BCL6 →read by rule
“A degrader that targets B-cell lymphoma 6 protein (BCL6; BCL-6), ”NCIt, by rule

Other programs on BCL6

ProgramCompanyFurthest phaseStudies
BCL6 Molecular Glue LY4584180ruleEli Lillyphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07082803Lymphoma · United States, Australia, Canada1RecruitingSep 2030180

How it is read

Names in the registry

  • “TLN-121”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.